Thermo Fisher Scientific Inc. $TMO Shares Sold by Wedge Capital Management L L P NC

Key Points

• Wedge Capital Management cut its Thermo Fisher Scientific stake by 93.3% in the second quarter, selling 11,212 shares and retaining 809 shares worth approximately $406,000. Institutional investors collectively own 89.23% of TMO.
• Thermo Fisher reported strong quarterly results, with adjusted EPS of $6.03 beating estimates of $5.71 and revenue of $11.99 billion rising 10.5% year over year. The company issued fiscal 2026 EPS guidance of $24.93–$25.33.
• Several analysts remain bullish, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $619.41. The company also declared a quarterly dividend of $0.47 per share, for an annualized yield of about 0.3%.

Wedge Capital Management L L P NC lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 93.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 809 shares of the medical research company's stock after selling 11,212 shares during the quarter. Wedge Capital Management L L P NC's holdings in Thermo Fisher Scientific were worth $406,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TMO. Brighton Jones LLC raised its holdings in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after acquiring an additional 988 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Darwin Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at $170,000. Raymond James Financial Inc. increased its stake in Thermo Fisher Scientific by 7.4% in the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company's stock valued at $315,781,000 after purchasing an additional 53,542 shares during the last quarter. Finally, California State Teachers Retirement System lifted its position in Thermo Fisher Scientific by 0.4% during the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company's stock worth $244,099,000 after buying an additional 2,262 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at approximately $71,191,194.75. This trade represents a 7.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 5,850 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total value of $3,393,000.00. Following the transaction, the vice president directly owned 14,784 shares in the company, valued at $8,574,720. This trade represents a 28.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 52,053 shares of company stock valued at $30,643,589 over the last ninety days. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Trading Down 1.3%

NYSE TMO opened at $588.17 on Friday. The firm has a market capitalization of $217.47 billion, a price-to-earnings ratio of 31.64, a PEG ratio of 2.39 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $643.99. The company's 50 day moving average price is $529.37 and its 200 day moving average price is $509.58.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the previous year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 10.11%.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a report on Friday, April 24th. Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, July 14th. Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, August 5th. Finally, Barclays lifted their price target on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source